US5415868A - Caplets with gelatin cover and process for making same - Google Patents

Caplets with gelatin cover and process for making same Download PDF

Info

Publication number
US5415868A
US5415868A US08/074,064 US7406493A US5415868A US 5415868 A US5415868 A US 5415868A US 7406493 A US7406493 A US 7406493A US 5415868 A US5415868 A US 5415868A
Authority
US
United States
Prior art keywords
hard
medicament
caplet
gelatin capsule
shrink
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/074,064
Inventor
Floyd S. Smith
Mark E. Crim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
L Perrigo Co
Perrigo Co
Original Assignee
L Perrigo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22117488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US5415868(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by L Perrigo Co filed Critical L Perrigo Co
Priority to US08/074,064 priority Critical patent/US5415868A/en
Assigned to PERRIGO COMPANY reassignment PERRIGO COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CRIM, MARK E., SMITH, FLOYD S.
Priority to US08/312,819 priority patent/US6126767A/en
Application granted granted Critical
Publication of US5415868A publication Critical patent/US5415868A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2873—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S53/00—Package making
    • Y10S53/90—Capsules

Definitions

  • the present invention relates to medicaments and processes for providing gelatin coverings for such medicaments.
  • Drug delivery systems are available in a great variety of shapes and forms, among the most common of which are coated compressed hard tablets, caplets and filled gelatin capsules.
  • the use of gelatin capsules for the encapsulation of medicinal agents has been a popular method for administering drugs because many patients prefer to swallow capsules and caplets rather than tablets.
  • Caplets are solid, oblong tablets which, although very popular as a drug delivery vehicle, have not reached the same level of consumer acceptance gelatin capsules once had. To solve this problem, the pharmaceutical industry has sought to combine the consumer acceptance of a capsule shape with a caplet.
  • the present invention thus provides a novel simulated capsule medicament consisting of a solid core, such as a caplet, covered with two shrink-wrapped, hard-shell gelatin capsule halves.
  • the solid cores are covered with the hard-shell gelatin capsule halves by individually shrink-wrapping onto first one end of the core a first hard-shell gelatin capsule half and then individually shrink-wrapping onto a second end of the core a second hard-shell gelatin capsule half.
  • the two shrink-wrapped capsule halves preferably abut, but do not overlap, at a point about midway of a longitudinal axis of the medicament. Any gap between the two shrink-wrapped capsule halves may be covered by transverse banding the covered caplet with a standard gelatin band.
  • the two shrink-wrapped hard-shell gelatin capsule halves may be of different colors to form a simulated two color, capsule-like medicament.
  • FIG. 1 is an exploded view of the shrink-wrapped hard-shell gelatin capsule covered dosage form of the present invention
  • FIG. 2 is a cross-sectional view along the elongated axis of an alternative embodiment of the shrink-wrapped hard-shell gelatin capsule covered dosage form of the present invention.
  • FIG. 3 is a diagrammatic view of the sequence for producing the shrink-wrapped hard-shell gelatin capsule covered caplet of the present invention.
  • the basic components of the present medicament include first and second hard-shell gelatin capsule halves, such as commercially marketed by R. P. Scherer Corporation, Troy, Mich.
  • the diameter and lengths of the halves are selected so that they are not slip-fit joinable and then allow a medicinal caplet for oral administration to fit within the capsule halves.
  • the hard gelatin capsule halves can be any size from 4 to 000 and preferably the capsule halves contain different colored gelatin to facilitate the simulation of a capsule medicament.
  • the medicinal caplet can contain any of the many medicinals presently marketed over-the-counter or on a prescription basis such as aspirin, acetaminophen and ibuprofen.
  • Other well-known medicinals, such as antihistamines and decongestants can be included as well.
  • the present invention provides a simulated gelatin capsule medicament 10.
  • medicament 10 comprises a caplet-shaped core 12 covered with a pair of hard-shell gelatin capsule halves 14 and 16.
  • Capsule halves 14 and 16 have a combined length of less than or equal to the length of core 12. That is, when capsule halves 14 and 16 are slipped onto core 12, their ends may abut, but will not overlap. Overlapping of the ends is also prevented since capsule halves 14 and 16 are of the same diameter.
  • hard-shell capsule halves 14 and 16 each having the same length are placed onto core 12.
  • the annular ends of capsule halves 14 and 16 abut each other at a point about midway 11 of the longitudinal axis of core 12.
  • FIG. 3 illustrates a diagrammatic view of the manufacturing sequence for producing the shrink-wrapped hard-shell gelatin capsule covered caplet of the present invention.
  • a first end 13 of core 12 is inserted (block 30) into a holder (not shown) leaving a second end 15 of core 12 exposed.
  • a dot of liquid gelatin 19 is then placed on exposed second end 15 of core 12, as shown by block 32.
  • Hard-shell gelatin capsule half 16 is then placed over second end 15 of core 12 and into contact with gelatin dot 19 (block 34) so that the shell is held in place on core 12 to form a first half-shell/core combination.
  • the first combination is dipped (block 36) into a tank (not shown) of hot water (90-95 degrees C.) up to the annular edge of capsule half 16 for a period of about 4 seconds to allow the hard gelatin shell to hydrate and plasticize.
  • Gelatin dot 19 is chosen to have a melting point of greater than the temperature of the water so that capsule half 16 can remain in place on second end 15 of core 12.
  • hard-shell gelatin capsule half 16 is then permitted, and preferably caused, to dry (block 38) to cause hard-shell gelatin capsule half 16 to shrink to fit the form of second end 15 of core 12 to form a first shrink-wrap gelatin hard-shell covering/core combination.
  • First end 13 of core 12 is then displaced from the holder (block 40).
  • the now covered second end of the first covering/core combination is then inserted into the holder (block 42) and a dot of liquid gelatin 18 is placed onto exposed first end 13 of core 12 (block 44).
  • Hard-shell gelatin capsule half 14 is then placed (block 46) over first end 13 of core 12 and into contact with gelatin dot 18 so that the shell is held in place on core 12 to form a second half-shell/core combination.
  • the second combination is then dipped (block 48) into the hot water bath to allow it to hydrate and plasticize.
  • gelatin dot 19 has a melting point temperature that is higher than the temperature of the water.
  • the plasticized hard-shell capsule half 14 dries (block 50) and shrinks to fit the form of first end 13 of core 12 to form a second shrink-wrap gelatin hard-shell covering/core combination.
  • the covering/core combination is then displaced from the holder (block 52).
  • shrink-wrapped capsule halves 14 and 16 are substantially in intimate contact with core 12, i.e. capsule halves 14 and have been shrink-wrapped onto core 12.
  • shrink-wrapped capsule halves 14 and 16 sometimes do not abut at a point about midway of a longitudinal axis of the core. This is because capsule halves 14 and 16 may shrink upon completion of treatment which may cause them to pull back a few thousandths from each other at the middle of core 12. If this occurs, a standard gelatin "belly" band 17 can be added to core 12 to cover the gap between capsule halves 14 and 16 to facilitate the simulation of a gelatin capsule medicament.
  • gelatin hard shell capsules halves 14 and 16 need to be in the hot water tank to plasticize depends on the pigments present in the capsules. For example, red pigments appear to be the softest formulations and require the shortest dip times.
  • White capsule halves are hard formulations and require relatively long dip times. Yellow and clear capsule halves require dip times which are between the dip times needed for red capsules and white capsules.
  • the proper level of hydration needed to plasticize particular gelatin hard shell capsules can be determined by routine experimentation. To minimize processing difficulties, however, it is anticipated that the level of hydration should be as little as possible while retaining the ability of the capsule to shrink upon drying.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Disclosed is a novel simulated capsule medicament consisting of a solid core covered with two shrink-wrapped, hard-shell gelatin capsule halves. The solid cores are covered with the hard-shell gelatin capsule halves by individually shrink-wrapping onto first one end of the core a first hard-shell gelatin capsule half and then individually shrink-wrapping onto a second end of the core a second hard-shell gelatin capsule half.

Description

FIELD OF THE INVENTION
The present invention relates to medicaments and processes for providing gelatin coverings for such medicaments.
BACKGROUND OF THE INVENTION
Drug delivery systems are available in a great variety of shapes and forms, among the most common of which are coated compressed hard tablets, caplets and filled gelatin capsules. The use of gelatin capsules for the encapsulation of medicinal agents has been a popular method for administering drugs because many patients prefer to swallow capsules and caplets rather than tablets.
Caplets are solid, oblong tablets which, although very popular as a drug delivery vehicle, have not reached the same level of consumer acceptance gelatin capsules once had. To solve this problem, the pharmaceutical industry has sought to combine the consumer acceptance of a capsule shape with a caplet.
Several proposals have suggested forming caplets and subsequently coating them to simulate a capsule-like medicament. One such proposal is represented by U.S. Pat. Nos. 5,089,270 and 5,213,738 assigned to the present assignee. Other proposals are represented by U.S. Pat. Nos. 4,820,524; 4,928,840 and 5,146,730. None of these proposals contemplate producing capsule-like medicaments by individually covering first one end of a caplet with a hard shell capsule half and shrinking the capsule half onto the caplet, and then covering the other end of each caplet with a second hard shell capsule half and shrinking the capsule half onto the caplet, without contacting the first shrink-wrapped capsule half, to form a gelatin covered caplet.
SUMMARY OF THE INVENTION
The present invention thus provides a novel simulated capsule medicament consisting of a solid core, such as a caplet, covered with two shrink-wrapped, hard-shell gelatin capsule halves. The solid cores are covered with the hard-shell gelatin capsule halves by individually shrink-wrapping onto first one end of the core a first hard-shell gelatin capsule half and then individually shrink-wrapping onto a second end of the core a second hard-shell gelatin capsule half. The two shrink-wrapped capsule halves preferably abut, but do not overlap, at a point about midway of a longitudinal axis of the medicament. Any gap between the two shrink-wrapped capsule halves may be covered by transverse banding the covered caplet with a standard gelatin band. In one embodiment, the two shrink-wrapped hard-shell gelatin capsule halves may be of different colors to form a simulated two color, capsule-like medicament.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is an exploded view of the shrink-wrapped hard-shell gelatin capsule covered dosage form of the present invention;
FIG. 2 is a cross-sectional view along the elongated axis of an alternative embodiment of the shrink-wrapped hard-shell gelatin capsule covered dosage form of the present invention; and
FIG. 3 is a diagrammatic view of the sequence for producing the shrink-wrapped hard-shell gelatin capsule covered caplet of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The basic components of the present medicament include first and second hard-shell gelatin capsule halves, such as commercially marketed by R. P. Scherer Corporation, Troy, Mich. The diameter and lengths of the halves are selected so that they are not slip-fit joinable and then allow a medicinal caplet for oral administration to fit within the capsule halves. The hard gelatin capsule halves can be any size from 4 to 000 and preferably the capsule halves contain different colored gelatin to facilitate the simulation of a capsule medicament.
The medicinal caplet can contain any of the many medicinals presently marketed over-the-counter or on a prescription basis such as aspirin, acetaminophen and ibuprofen. Other well-known medicinals, such as antihistamines and decongestants can be included as well.
The present invention provides a simulated gelatin capsule medicament 10. As shown in FIGS. 1 and 2, medicament 10 comprises a caplet-shaped core 12 covered with a pair of hard-shell gelatin capsule halves 14 and 16. Capsule halves 14 and 16 have a combined length of less than or equal to the length of core 12. That is, when capsule halves 14 and 16 are slipped onto core 12, their ends may abut, but will not overlap. Overlapping of the ends is also prevented since capsule halves 14 and 16 are of the same diameter. In a preferred embodiment, hard- shell capsule halves 14 and 16 each having the same length are placed onto core 12. In this embodiment, the annular ends of capsule halves 14 and 16 abut each other at a point about midway 11 of the longitudinal axis of core 12.
FIG. 3 illustrates a diagrammatic view of the manufacturing sequence for producing the shrink-wrapped hard-shell gelatin capsule covered caplet of the present invention. With reference to the figures, in the manufacturing process a first end 13 of core 12 is inserted (block 30) into a holder (not shown) leaving a second end 15 of core 12 exposed. A dot of liquid gelatin 19 is then placed on exposed second end 15 of core 12, as shown by block 32. Hard-shell gelatin capsule half 16 is then placed over second end 15 of core 12 and into contact with gelatin dot 19 (block 34) so that the shell is held in place on core 12 to form a first half-shell/core combination. The first combination is dipped (block 36) into a tank (not shown) of hot water (90-95 degrees C.) up to the annular edge of capsule half 16 for a period of about 4 seconds to allow the hard gelatin shell to hydrate and plasticize. Gelatin dot 19 is chosen to have a melting point of greater than the temperature of the water so that capsule half 16 can remain in place on second end 15 of core 12. After removal from the tank, hard-shell gelatin capsule half 16 is then permitted, and preferably caused, to dry (block 38) to cause hard-shell gelatin capsule half 16 to shrink to fit the form of second end 15 of core 12 to form a first shrink-wrap gelatin hard-shell covering/core combination. First end 13 of core 12 is then displaced from the holder (block 40).
The now covered second end of the first covering/core combination is then inserted into the holder (block 42) and a dot of liquid gelatin 18 is placed onto exposed first end 13 of core 12 (block 44). Hard-shell gelatin capsule half 14 is then placed (block 46) over first end 13 of core 12 and into contact with gelatin dot 18 so that the shell is held in place on core 12 to form a second half-shell/core combination. The second combination is then dipped (block 48) into the hot water bath to allow it to hydrate and plasticize. As with gelatin dot 19, gelatin dot 18 has a melting point temperature that is higher than the temperature of the water. The plasticized hard-shell capsule half 14 dries (block 50) and shrinks to fit the form of first end 13 of core 12 to form a second shrink-wrap gelatin hard-shell covering/core combination. The covering/core combination is then displaced from the holder (block 52).
After completion of the shrink-wrapping process, examination of the medicament reveals that the two hard-shell gelatin capsule halves 14 and 16 are substantially in intimate contact with core 12, i.e. capsule halves 14 and have been shrink-wrapped onto core 12. As shown in FIG. 2, shrink-wrapped capsule halves 14 and 16 sometimes do not abut at a point about midway of a longitudinal axis of the core. This is because capsule halves 14 and 16 may shrink upon completion of treatment which may cause them to pull back a few thousandths from each other at the middle of core 12. If this occurs, a standard gelatin "belly" band 17 can be added to core 12 to cover the gap between capsule halves 14 and 16 to facilitate the simulation of a gelatin capsule medicament.
The amount of time gelatin hard shell capsules halves 14 and 16 need to be in the hot water tank to plasticize depends on the pigments present in the capsules. For example, red pigments appear to be the softest formulations and require the shortest dip times. White capsule halves, on the other hand, are hard formulations and require relatively long dip times. Yellow and clear capsule halves require dip times which are between the dip times needed for red capsules and white capsules.
The proper level of hydration needed to plasticize particular gelatin hard shell capsules can be determined by routine experimentation. To minimize processing difficulties, however, it is anticipated that the level of hydration should be as little as possible while retaining the ability of the capsule to shrink upon drying.
Those skilled in the art to which this invention pertains will appreciate that the foregoing descriptions of presently preferred embodiments of various aspects of this invention are primarily illustrative and exemplary and are not exhaustive of all of the ways in which the invention can be embodied. Various modifications and alterations can be made to the products, formulations, procedures, and apparatus which has been described without departing from the scope of this invention, as defined by the appended claims.

Claims (11)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. A medicament comprising:
(a) a solid generally cylindrical caplet with a longitudinal axis and having a first and a second end at opposite ends of said longitudinal axis;
(b) a first hard-shell gelatin capsule half shrink-wrapped on said second end of said caplet;
(c) a second hard-shell gelatin capsule half shrink-wrapped on said first end of said caplet and abutting, but not overlapping, said shrink-wrapped first hard-shell gelatin capsule half wherein said first and second hard-shell gelatin capsule halves have substantially the same diameter.
2. The medicament of claim 1 wherein said first and second shrink wrapped capsule halves abut at about a midway point of said longitudinal axis of said medicament.
3. The medicament of claim 1 further including a pharmaceutically acceptable adhesive situated between each caplet end and the adjacent inner surface of said first and second capsule halves.
4. A medicament comprising:
(a) a solid caplet having a first and a second end, said caplet comprising a generally cylindrical shape;
(b) a first hard-shell gelatin capsule half of a first color shrink-wrapped on said second end of said caplet;
(c) a second hard-shell gelatin capsule half, of a color different from said first color, shrink-wrapped on said first end of said caplet and abutting, but not overlapping, said shrink-wrapped first hard-shell gelatin capsule half at about a midway point of a longitudinal axis of said medicament wherein said first and second hard-shell gelatin capsule halves have substantially the same diameter.
5. The medicament of claim 4 wherein said first gelatin capsule half is red.
6. The medicament of claim 4 wherein said second gelatin capsule half is white.
7. The medicament of claim 4 wherein said caplet comprises a width and length, wherein said length is at least 2.5 times the width.
8. The medicament of claim 4 further including a pharmaceutically acceptable adhesive situated between each caplet end and the adjacent inner surface of said first and second capsule halves.
9. The medicament as defined in claim 1 and further including a gelatin band extending transversely around said caplet to overly the abutting ends of said hard shell gelatin capsule halves.
10. The medicament as defined in claim 9 wherein said first hard-shell gelatin capsule half has a first color and said second hard-shell gelatin capsule half has a color different than said first color.
11. The medicament as defined in claim 4 and further including a gelatin band extending transversely around said caplet to overly the abutting ends of said hard shell gelatin capsule halves.
US08/074,064 1993-06-09 1993-06-09 Caplets with gelatin cover and process for making same Expired - Fee Related US5415868A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US08/074,064 US5415868A (en) 1993-06-09 1993-06-09 Caplets with gelatin cover and process for making same
US08/312,819 US6126767A (en) 1993-06-09 1994-09-27 Method of manufacturing caplets with a gelatin cover

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/074,064 US5415868A (en) 1993-06-09 1993-06-09 Caplets with gelatin cover and process for making same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/312,819 Division US6126767A (en) 1993-06-09 1994-09-27 Method of manufacturing caplets with a gelatin cover

Publications (1)

Publication Number Publication Date
US5415868A true US5415868A (en) 1995-05-16

Family

ID=22117488

Family Applications (2)

Application Number Title Priority Date Filing Date
US08/074,064 Expired - Fee Related US5415868A (en) 1993-06-09 1993-06-09 Caplets with gelatin cover and process for making same
US08/312,819 Expired - Lifetime US6126767A (en) 1993-06-09 1994-09-27 Method of manufacturing caplets with a gelatin cover

Family Applications After (1)

Application Number Title Priority Date Filing Date
US08/312,819 Expired - Lifetime US6126767A (en) 1993-06-09 1994-09-27 Method of manufacturing caplets with a gelatin cover

Country Status (1)

Country Link
US (2) US5415868A (en)

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498255A (en) * 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
US5511361A (en) * 1992-08-07 1996-04-30 Warner-Lambert Company Encapsulation method
US5824338A (en) * 1996-08-19 1998-10-20 L. Perrigo Company Caplet and gelatin covering therefor
US6080426A (en) * 1994-12-16 2000-06-27 Warner-Lamberg Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
US6113945A (en) * 1996-02-26 2000-09-05 L. Perrigo Company Multi-colored medicament
US6245350B1 (en) 1994-12-16 2001-06-12 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
WO2003026612A2 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Dosage forms having an inner core and outer shell
US20030068373A1 (en) * 2001-09-28 2003-04-10 Joseph Luber Immediate release tablet
US20030068367A1 (en) * 2001-09-28 2003-04-10 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
WO2003028619A2 (en) 2001-09-28 2003-04-10 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
WO2003028989A1 (en) 2001-09-28 2003-04-10 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
WO2003028620A1 (en) 2001-09-28 2003-04-10 Mcneil-Ppc, Inc. Method for making an insert
US20030215563A1 (en) * 2002-05-15 2003-11-20 Mcneil-Ppc, Inc. Process for enrobing a core
US20040081695A1 (en) * 2002-09-28 2004-04-29 Sowden Harry S Dosage forms having an inner core and an outer shell
US20040126425A1 (en) * 2001-09-28 2004-07-01 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US20040156902A1 (en) * 2002-09-28 2004-08-12 Der-Yang Lee Composite dosage forms having an inlaid portion
US20040175425A1 (en) * 2001-09-28 2004-09-09 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US20050074514A1 (en) * 2003-10-02 2005-04-07 Anderson Oliver B. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms
US20050152970A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
EP1602363A1 (en) 2004-06-04 2005-12-07 McNeil-PPC, Inc. Immediate release dosage form comprising shell having openings therein
WO2006022805A1 (en) 2004-07-23 2006-03-02 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US7055295B1 (en) * 1997-10-17 2006-06-06 Shin-Etsu Chemical Co., Ltd. Annular sustained release pheromone-dispenser and its installation tool
US20060121145A1 (en) * 2004-12-07 2006-06-08 Sowden Harry S System and process for providing at least one opening in dosage forms
US20060118991A1 (en) * 2004-12-07 2006-06-08 Sowden Harry S System and process for providing at least one opening in dosage forms
US20060233881A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Modified release dosage form
US7169450B2 (en) 2002-05-15 2007-01-30 Mcneil-Ppc, Inc. Enrobed core
US20070190131A1 (en) * 2006-02-10 2007-08-16 Perry Ronald L Press-fit rapid release medicament and method and apparatus of manufacturing
US20070231389A1 (en) * 2006-03-28 2007-10-04 Bunick Frank J Non-homogenous dosage form coatings
US20090110724A1 (en) * 2007-10-31 2009-04-30 Everett Laboratories, Inc. Compositions and methods for treatment of pain
US20090274731A1 (en) * 2006-05-24 2009-11-05 Abbott Gmbh & Co. Kg Production of enveloped pharmaceutical dosage forms
US20090287121A1 (en) * 2007-01-30 2009-11-19 Olympus Medical Systems Corp. Lumen passability checking device and methods of dissolving and manufacturing the device
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
EP2255795A1 (en) 2002-09-28 2010-12-01 McNeil-PPC, Inc. Immediate release dosage form comprising shell having openings therein
WO2012024360A2 (en) 2010-08-18 2012-02-23 Mcneil-Ppc, Inc. Tablet sleeve for improved performance
US20150196518A1 (en) * 2014-01-10 2015-07-16 Cadila Healthcare Limited Pharmaceutical compositions of mesalamine
US20160045442A1 (en) * 2014-08-13 2016-02-18 Cadila Healthcare Limited Stable pharmaceutical compositions of mesalamine
WO2018017553A2 (en) 2016-07-19 2018-01-25 Johnson & Johnson Consumer Inc. Tablets having discontinuous coated regions
US10583089B2 (en) 2016-07-19 2020-03-10 Johnson & Johnson Consumer Inc. Tablets having discontinuous coated regions

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
NZ555244A (en) * 2004-11-19 2010-06-25 Smithkline Beecham Corp Manufacture process for pharmaceutical product allowing delivery of a plurality of active agents
EP1836665B1 (en) 2004-11-19 2013-01-16 GlaxoSmithKline LLC Method for customized dispensing of variable dose drug combination products for individualizing of therapies
US8372225B2 (en) * 2005-11-18 2013-02-12 Glaxo Group Limited Machine and method for pharmaceutical and pharmaceutical-like product assembly
CN102639122A (en) 2009-12-07 2012-08-15 麦克内尔-Ppc股份有限公司 Partial dip coating of dosage forms for modified release
JP6027532B2 (en) * 2010-08-25 2016-11-16 セカンド、グラント、ルーファス スパーリング Improved enteric active substance delivery
EP3167869B1 (en) 2015-11-16 2025-02-12 Capsugel Belgium NV Tamperproof oral dosage form
EP3167870B1 (en) 2015-11-16 2024-01-03 Capsugel Belgium NV Tamperproof oral dosage form
WO2018029561A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions

Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1520940A (en) * 1922-03-01 1924-12-30 Dulitz August Adolf Process for the manufacture of sealing caps and for applying them onto the vessels to be sealed
US1657982A (en) * 1926-02-15 1928-01-31 Parke Davis & Co Process of manufacturing gelatin capsules for use as bottle caps
US1685392A (en) * 1925-08-12 1928-09-25 Cellacote Company Inc Preservative package and process of making the same
US1774258A (en) * 1929-07-08 1930-08-26 Raymond A English Duplex capsule or the like
US1931765A (en) * 1932-05-09 1933-10-24 Basil E Leever Beverage capsule
US2663130A (en) * 1946-12-26 1953-12-22 American Cyanamid Co Apparatus for producing symmetrical generally ellipsoidal capsules
US3983258A (en) * 1975-02-07 1976-09-28 Continental Can Company, Inc. Process of packaging edible products containing exposed bones
US4793119A (en) * 1986-10-20 1988-12-27 Paolo Maso Bander machine for drugs containing capsules
US4820524A (en) * 1987-02-20 1989-04-11 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4844906A (en) * 1987-03-25 1989-07-04 Kv Pharmaceutical Company Tamper evident pharmaceutical capsule
US4867983A (en) * 1987-02-20 1989-09-19 Mcneilab, Inc. Method for double dipping gelating coated caplets
US4928840A (en) * 1986-02-25 1990-05-29 American Home Products Corporation Tamper proof encapsulated medicaments
US4936074A (en) * 1988-11-17 1990-06-26 D. M. Graham Laboratories, Inc. Process for preparing solid encapsulated medicament
US4966771A (en) * 1987-02-20 1990-10-30 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4973480A (en) * 1987-03-25 1990-11-27 K.V. Pharmaceutical Co. Tamper evident pharmaceutical capsule
US5074426A (en) * 1986-11-13 1991-12-24 Warner-Lambert Company Dividable capsule
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
US5146730A (en) * 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US5188688A (en) * 1990-07-20 1993-02-23 Minnesota Mining And Manufacturing Company Method of sealing a gelatin capsule
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1937468A (en) * 1932-07-12 1933-11-28 Samson Cordage Works Wrapped article and method
US2770553A (en) * 1952-09-09 1956-11-13 American Cyanamid Co Soft gelatin encapsulation
GB1093286A (en) * 1965-02-15 1967-11-29 Biorex Laboratories Ltd Improvements in or relating to dosage unit forms for the administration of medicaments and diagnostic agents
US5317849A (en) * 1992-08-07 1994-06-07 Sauter Manufacturing Corporation Encapsulation equipment and method

Patent Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1520940A (en) * 1922-03-01 1924-12-30 Dulitz August Adolf Process for the manufacture of sealing caps and for applying them onto the vessels to be sealed
US1685392A (en) * 1925-08-12 1928-09-25 Cellacote Company Inc Preservative package and process of making the same
US1657982A (en) * 1926-02-15 1928-01-31 Parke Davis & Co Process of manufacturing gelatin capsules for use as bottle caps
US1774258A (en) * 1929-07-08 1930-08-26 Raymond A English Duplex capsule or the like
US1931765A (en) * 1932-05-09 1933-10-24 Basil E Leever Beverage capsule
US2663130A (en) * 1946-12-26 1953-12-22 American Cyanamid Co Apparatus for producing symmetrical generally ellipsoidal capsules
US3983258A (en) * 1975-02-07 1976-09-28 Continental Can Company, Inc. Process of packaging edible products containing exposed bones
US4928840A (en) * 1986-02-25 1990-05-29 American Home Products Corporation Tamper proof encapsulated medicaments
US4793119A (en) * 1986-10-20 1988-12-27 Paolo Maso Bander machine for drugs containing capsules
US5074426A (en) * 1986-11-13 1991-12-24 Warner-Lambert Company Dividable capsule
US4867983A (en) * 1987-02-20 1989-09-19 Mcneilab, Inc. Method for double dipping gelating coated caplets
US4966771A (en) * 1987-02-20 1990-10-30 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4820524A (en) * 1987-02-20 1989-04-11 Mcneilab, Inc. Gelatin coated caplets and process for making same
US4844906A (en) * 1987-03-25 1989-07-04 Kv Pharmaceutical Company Tamper evident pharmaceutical capsule
US4973480A (en) * 1987-03-25 1990-11-27 K.V. Pharmaceutical Co. Tamper evident pharmaceutical capsule
US4936074A (en) * 1988-11-17 1990-06-26 D. M. Graham Laboratories, Inc. Process for preparing solid encapsulated medicament
US5085033A (en) * 1988-11-17 1992-02-04 D. M. Graham Laboratories, Inc. Process for preparing a solid encapsulated medicament
US5146730A (en) * 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US5089270A (en) * 1990-05-15 1992-02-18 L. Perrigo Company Capsule-shaped tablet
US5213738A (en) * 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5188688A (en) * 1990-07-20 1993-02-23 Minnesota Mining And Manufacturing Company Method of sealing a gelatin capsule

Cited By (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5511361A (en) * 1992-08-07 1996-04-30 Warner-Lambert Company Encapsulation method
US5609010A (en) * 1992-08-07 1997-03-11 Warner-Lambert Company Encapsulation method
US5795588A (en) * 1992-08-07 1998-08-18 Warner-Lambert Company Encapsulated product
US5498255A (en) * 1993-08-17 1996-03-12 Alza Corporation Osmotic device for protracted pulsatile delivery of agent
US6080426A (en) * 1994-12-16 2000-06-27 Warner-Lamberg Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
US6245350B1 (en) 1994-12-16 2001-06-12 Warner-Lambert Company Process for encapsulation of caplets in a capsule and solid dosage forms obtainable by such process
US6113945A (en) * 1996-02-26 2000-09-05 L. Perrigo Company Multi-colored medicament
US5824338A (en) * 1996-08-19 1998-10-20 L. Perrigo Company Caplet and gelatin covering therefor
US7055295B1 (en) * 1997-10-17 2006-06-06 Shin-Etsu Chemical Co., Ltd. Annular sustained release pheromone-dispenser and its installation tool
US20050129763A1 (en) * 2001-09-28 2005-06-16 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US7323192B2 (en) 2001-09-28 2008-01-29 Mcneil-Ppc, Inc. Immediate release tablet
US20030068367A1 (en) * 2001-09-28 2003-04-10 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
WO2003028619A2 (en) 2001-09-28 2003-04-10 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
WO2003028989A1 (en) 2001-09-28 2003-04-10 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
WO2003028620A1 (en) 2001-09-28 2003-04-10 Mcneil-Ppc, Inc. Method for making an insert
WO2003026612A3 (en) * 2001-09-28 2003-06-26 Mcneil Ppc Inc Dosage forms having an inner core and outer shell
US20030124183A1 (en) * 2001-09-28 2003-07-03 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
WO2003026615A3 (en) * 2001-09-28 2003-07-31 Mcneil Ppc Inc Modified release dosage forms
WO2003026626A3 (en) * 2001-09-28 2003-10-16 Mcneil Ppc Inc Modified release dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
US20030217908A1 (en) * 2001-09-28 2003-11-27 Sowden Harry S. Method and apparatus for transferring substrates
US20040062804A1 (en) * 2001-09-28 2004-04-01 Der-Yang Lee Modified release dosage forms
US7972624B2 (en) 2001-09-28 2011-07-05 Shun-Por Li Method of manufacturing modified release dosage forms
US6742646B2 (en) 2001-09-28 2004-06-01 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US20040126425A1 (en) * 2001-09-28 2004-07-01 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US20040137057A1 (en) * 2001-09-28 2004-07-15 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US6767200B2 (en) 2001-09-28 2004-07-27 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US20090186082A1 (en) * 2001-09-28 2009-07-23 Shun-Por Li Method of manufacturing modified release dosage forms
US20040170750A1 (en) * 2001-09-28 2004-09-02 Bunick Frank J. Edible composition and dosage form comprising an edible shell
US20040175425A1 (en) * 2001-09-28 2004-09-09 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US20040191044A1 (en) * 2001-09-28 2004-09-30 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US20040213848A1 (en) * 2001-09-28 2004-10-28 Shun-Por Li Modified release dosage forms
US20040241236A1 (en) * 2001-09-28 2004-12-02 Shun-Por Li Modified release dosage forms
US20040241208A1 (en) * 2001-09-28 2004-12-02 Sowden Harry S. Fondant-based pharmaceutical composition
US6837696B2 (en) 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US20050019376A1 (en) * 2001-09-28 2005-01-27 Mcnally Gerard P. Dosage form containing a confectionery composition
US20090155372A1 (en) * 2001-09-28 2009-06-18 Shun-Por Li Method of manufacturing modified release dosage forms
US6880694B2 (en) 2001-09-28 2005-04-19 Harry S. Sowden Method and apparatus for transferring substrates
US7968120B2 (en) 2001-09-28 2011-06-28 Mcneil-Ppc, Inc. Modified release dosage forms
US20050147677A1 (en) * 2001-09-28 2005-07-07 Sowden Harry S. Systems, methods and apparatuses for manufacturing dosage forms
US8114328B2 (en) 2001-09-28 2012-02-14 Mcneil-Ppc, Inc. Method of coating a dosage form comprising a first medicant
US8545887B2 (en) 2001-09-28 2013-10-01 Mcneil-Ppc, Inc. Modified release dosage forms
US8673190B2 (en) 2001-09-28 2014-03-18 Mcneil-Ppc, Inc. Method for manufacturing dosage forms
US6982094B2 (en) 2001-09-28 2006-01-03 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US7361006B2 (en) 2001-09-28 2008-04-22 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
WO2003026626A2 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Modified release dosage forms
WO2003026612A2 (en) * 2001-09-28 2003-04-03 Mcneil-Ppc, Inc. Dosage forms having an inner core and outer shell
US7323129B2 (en) 2001-09-28 2008-01-29 Omj Ireland Limited Systems, methods and apparatuses for manufacturing dosage forms
US20030068373A1 (en) * 2001-09-28 2003-04-10 Joseph Luber Immediate release tablet
US7297345B2 (en) 2001-09-28 2007-11-20 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US20060246136A1 (en) * 2001-09-28 2006-11-02 Sowden Harry S Systems, methods and apparatuses for manufacturing dosage forms
US7240785B2 (en) 2001-09-28 2007-07-10 Mcneil-Ppc, Inc. Method and apparatus for transferring substrates
US7182199B2 (en) 2001-09-28 2007-02-27 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US7217381B2 (en) 2001-09-28 2007-05-15 Mcneil-Ppc, Inc. Systems, methods and apparatuses for manufacturing dosage forms
US7955652B2 (en) 2002-05-15 2011-06-07 Mcneil-Ppc, Inc. Enrobed core
US20030215563A1 (en) * 2002-05-15 2003-11-20 Mcneil-Ppc, Inc. Process for enrobing a core
US7169450B2 (en) 2002-05-15 2007-01-30 Mcneil-Ppc, Inc. Enrobed core
US20080069880A1 (en) * 2002-05-15 2008-03-20 Bunick Frank J Enrobed core
US6946156B2 (en) 2002-05-15 2005-09-20 Mcneil-Ppc, Inc. Process for enrobing a core
EP2255795A1 (en) 2002-09-28 2010-12-01 McNeil-PPC, Inc. Immediate release dosage form comprising shell having openings therein
US7807197B2 (en) 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US20040081695A1 (en) * 2002-09-28 2004-04-29 Sowden Harry S Dosage forms having an inner core and an outer shell
US20040156902A1 (en) * 2002-09-28 2004-08-12 Der-Yang Lee Composite dosage forms having an inlaid portion
US20050074514A1 (en) * 2003-10-02 2005-04-07 Anderson Oliver B. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms
WO2006078242A1 (en) 2003-10-02 2006-07-27 Mcneil-Ppc, Inc. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms
US11298324B2 (en) 2004-01-13 2022-04-12 Johnson & Johnson Consumer Inc. Rapidly disintegrating gelatinous coated tablets
US20050152970A1 (en) * 2004-01-13 2005-07-14 Rinker Roger A. Rapidly disintegrating gelatinous coated tablets
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US8815290B2 (en) 2004-01-13 2014-08-26 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US10632078B2 (en) 2004-01-13 2020-04-28 Johnson & Johnson Consumer Inc. Rapidly disintegrating gelatinous coated tablets
US9149438B2 (en) 2004-01-13 2015-10-06 Johnson & Johnson Consumer Inc. Rapidly disintegrating gelatinous coated tablets
US7879354B2 (en) 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US20110086098A1 (en) * 2004-01-13 2011-04-14 Rinker Roger A Rapidly disintegrating gelatinous coated tablets
US10092521B2 (en) 2004-01-13 2018-10-09 Johnson & Johnson Consumer Inc. Rapidly disintegrating gelatinous coated tablets
EP1602363A1 (en) 2004-06-04 2005-12-07 McNeil-PPC, Inc. Immediate release dosage form comprising shell having openings therein
EP2098224A1 (en) 2004-07-23 2009-09-09 Mcneil-PPC, Inc Rapidly disintegrating gelatinous coated tablets
WO2006022805A1 (en) 2004-07-23 2006-03-02 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US20060121145A1 (en) * 2004-12-07 2006-06-08 Sowden Harry S System and process for providing at least one opening in dosage forms
US7404708B2 (en) 2004-12-07 2008-07-29 Mcneil-Ppc, Inc. System and process for providing at least one opening in dosage forms
US20060118991A1 (en) * 2004-12-07 2006-06-08 Sowden Harry S System and process for providing at least one opening in dosage forms
US20090148523A1 (en) * 2004-12-07 2009-06-11 Sowden Harry S System and process for providing at least one opening in dosage forms
US7530804B2 (en) 2004-12-07 2009-05-12 Mcneil-Ppc, Inc. System and process for providing at least one opening in dosage forms
US20060233881A1 (en) * 2005-04-15 2006-10-19 Sowden Harry S Modified release dosage form
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US20070190131A1 (en) * 2006-02-10 2007-08-16 Perry Ronald L Press-fit rapid release medicament and method and apparatus of manufacturing
US20070231389A1 (en) * 2006-03-28 2007-10-04 Bunick Frank J Non-homogenous dosage form coatings
US20090274731A1 (en) * 2006-05-24 2009-11-05 Abbott Gmbh & Co. Kg Production of enveloped pharmaceutical dosage forms
US20090287121A1 (en) * 2007-01-30 2009-11-19 Olympus Medical Systems Corp. Lumen passability checking device and methods of dissolving and manufacturing the device
US20090110724A1 (en) * 2007-10-31 2009-04-30 Everett Laboratories, Inc. Compositions and methods for treatment of pain
WO2012024360A2 (en) 2010-08-18 2012-02-23 Mcneil-Ppc, Inc. Tablet sleeve for improved performance
US20150196518A1 (en) * 2014-01-10 2015-07-16 Cadila Healthcare Limited Pharmaceutical compositions of mesalamine
US20160045442A1 (en) * 2014-08-13 2016-02-18 Cadila Healthcare Limited Stable pharmaceutical compositions of mesalamine
WO2018017553A2 (en) 2016-07-19 2018-01-25 Johnson & Johnson Consumer Inc. Tablets having discontinuous coated regions
US10583089B2 (en) 2016-07-19 2020-03-10 Johnson & Johnson Consumer Inc. Tablets having discontinuous coated regions
US11576867B2 (en) 2016-07-19 2023-02-14 Johnson & Johnson Consumer Inc. Tablets having discontinuous coated regions

Also Published As

Publication number Publication date
US6126767A (en) 2000-10-03

Similar Documents

Publication Publication Date Title
US5415868A (en) Caplets with gelatin cover and process for making same
US5824338A (en) Caplet and gelatin covering therefor
US5464631A (en) Encapsulated dosage forms
US4928840A (en) Tamper proof encapsulated medicaments
EP0395431B1 (en) Subcoated simulated capsule-like medicament
US5074426A (en) Dividable capsule
AU633394B2 (en) Dual subcoated simulated capsule-like medicament
US4867983A (en) Method for double dipping gelating coated caplets
AU604845B2 (en) Gelatin coated caplets and process for making same
US5456919A (en) Capsule and caplet combination
US6113945A (en) Multi-colored medicament
AU682880B2 (en) Soft-shelled gelatin encapsulated particles
CA2033414A1 (en) Capsule and caplet combination
CA2117927C (en) Caplets with gelatin cover and process for making same
JP3877232B2 (en) Caplet with gelatin cover and manufacturing method thereof
AU687420B2 (en) Soft-shelled gelatin encapsulated particles
AU603614B2 (en) Dividable capsule
WO2006031584A2 (en) Quick dissolve medicament and method of manufacturing
KR200225675Y1 (en) Tablet having shape of capsule
PH26940A (en) Apparatus for gelatin coating caplets

Legal Events

Date Code Title Description
AS Assignment

Owner name: PERRIGO COMPANY, MICHIGAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SMITH, FLOYD S.;CRIM, MARK E.;REEL/FRAME:006625/0185

Effective date: 19930607

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20030516